YS Biopharma Co., Ltd. (NASDAQ:YS – Get Free Report) traded up 7.6% during trading on Friday . The company traded as high as $0.85 and last traded at $0.84. 398,477 shares traded hands during trading, an increase of 131% from the average session volume of 172,401 shares. The stock had previously closed at $0.78.
YS Biopharma Trading Up 7.6 %
The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average price of $0.52 and a 200 day moving average price of $0.67.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in YS Biopharma stock. Ovata Capital Management Ltd acquired a new position in shares of YS Biopharma Co., Ltd. (NASDAQ:YS – Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 150,000 shares of the company’s stock, valued at approximately $153,000. Ovata Capital Management Ltd owned approximately 0.16% of YS Biopharma as of its most recent filing with the Securities & Exchange Commission. 52.64% of the stock is currently owned by institutional investors and hedge funds.
About YS Biopharma
YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
Read More
- Five stocks we like better than YS Biopharma
- Which Wall Street Analysts are the Most Accurate?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- How to Use the MarketBeat Dividend Calculator
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Overbought Stocks Explained: Should You Trade Them?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for YS Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YS Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.